Serabelisib

Generic Name
Serabelisib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H17N5O3
CAS Number
1268454-23-4
Unique Ingredient Identifier
43J9Q56T3W
Background

Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer

First Posted Date
2024-06-17
Last Posted Date
2024-12-18
Lead Sponsor
Faeth Therapeutics
Target Recruit Count
40
Registration Number
NCT06463028
Locations
🇺🇸

Women's Cancer Care Associates, LLC, Albany, New York, United States

🇺🇸

Avera Cancer Institute, Sioux Falls, South Dakota, United States

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

First Posted Date
2022-03-29
Last Posted Date
2024-07-03
Lead Sponsor
Faeth Therapeutics
Target Recruit Count
68
Registration Number
NCT05300048
Locations
🇺🇸

New Jersey Cancer Care, PA, Belleville, New Jersey, United States

🇺🇸

Englewood Health, Englewood, New Jersey, United States

🇺🇸

Northwell Health, Lake Success, New York, United States

and more 14 locations

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

First Posted Date
2019-08-29
Last Posted Date
2020-05-21
Lead Sponsor
Petra Pharma
Target Recruit Count
60
Registration Number
NCT04073680
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy